Jane L. Roberts

2.4k total citations
69 papers, 1.9k citations indexed

About

Jane L. Roberts is a scholar working on Molecular Biology, Epidemiology and Oncology. According to data from OpenAlex, Jane L. Roberts has authored 69 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Molecular Biology, 29 papers in Epidemiology and 18 papers in Oncology. Recurrent topics in Jane L. Roberts's work include Autophagy in Disease and Therapy (27 papers), Histone Deacetylase Inhibitors Research (17 papers) and Endoplasmic Reticulum Stress and Disease (12 papers). Jane L. Roberts is often cited by papers focused on Autophagy in Disease and Therapy (27 papers), Histone Deacetylase Inhibitors Research (17 papers) and Endoplasmic Reticulum Stress and Disease (12 papers). Jane L. Roberts collaborates with scholars based in United States, Australia and United Kingdom. Jane L. Roberts's co-authors include Laurence Booth, Paul Dent, Andrew Poklepovic, John M. Kirkwood, Mehrad Tavallai, Nichola Cruickshanks, Alshad S. Lalani, John F. Hancock, Richard E. Cutler and Steven Grant and has published in prestigious journals such as Circulation, Cancer Research and Analytical Biochemistry.

In The Last Decade

Jane L. Roberts

68 papers receiving 1.9k citations

Peers

Jane L. Roberts

EPIDE

ONCOL

IMMUN

Laurence Booth United States

Hao Yan China

Katherine L. Cook United States

Shun-ichiro Iemura Japan

Bruna Pucci Italy

Olivier Geneste France

Valentina Sica France

Lisha Zhou China

Eleanna Kaffe United States

Hongxiu Yu China

Laurence Booth United States

Jane L. Roberts

1.6k ×1.4

778 ×1.5

EPIDE

582 ×1.3

ONCOL

434 ×1.4

270 ×1.1

IMMUN

Citations per year, relative to Jane L. Roberts Jane L. Roberts (= 1×) peers Laurence Booth

Countries citing papers authored by Jane L. Roberts

Since Specialization

Citations

This map shows the geographic impact of Jane L. Roberts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane L. Roberts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane L. Roberts more than expected).

Fields of papers citing papers by Jane L. Roberts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane L. Roberts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane L. Roberts. The network helps show where Jane L. Roberts may publish in the future.

Co-authorship network of co-authors of Jane L. Roberts

This figure shows the co-authorship network connecting the top 25 collaborators of Jane L. Roberts. A scholar is included among the top collaborators of Jane L. Roberts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane L. Roberts. Jane L. Roberts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Booth, Michael R., Laurence Booth, Jane L. Roberts, Cameron West, & Paul Dent. (2025). GZ17-6.02 interacts with carboplatin and etoposide to kill neuroblastoma cells. Anti-Cancer Drugs. 36(6). 478–488. 1 indexed citations

Booth, Laurence, Jane L. Roberts, Cameron West, & Paul Dent. (2024). GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells. Oncotarget. 15(1). 159–174. 2 indexed citations

Booth, Laurence, Jane L. Roberts, Cameron West, & Paul Dent. (2022). GZ17-6.02 kills prostate cancer cells in vitro and in vivo. Frontiers in Oncology. 12. 1045459–1045459. 7 indexed citations

Caillaud, Martial, Nipa Patel, M Wood, et al.. (2021). Targeting Peroxisome Proliferator-Activated Receptor-α (PPAR- α) to reduce paclitaxel-induced peripheral neuropathy. Brain Behavior and Immunity. 93. 172–185. 38 indexed citations

Roberts, Jane L., Andrew Poklepovic, Laurence Booth, & Paul Dent. (2020). The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells. Cellular Signalling. 70. 109573–109573. 26 indexed citations

Dent, Paul, Laurence Booth, Jane L. Roberts, Andrew Poklepovic, & John F. Hancock. (2020). Fingolimod Augments Monomethylfumarate Killing of GBM Cells. Frontiers in Oncology. 10. 22–22. 11 indexed citations

Caillaud, Martial, et al.. (2020). Deficit in voluntary wheel running in chronic inflammatory and neuropathic pain models in mice: Impact of sex and genotype. Behavioural Brain Research. 399. 113009–113009. 13 indexed citations

Booth, Laurence, Jane L. Roberts, & Paul Dent. (2019). The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib. Seminars in Cancer Biology. 66. 129–139. 64 indexed citations

Booth, Laurence, Jane L. Roberts, John M. Kirkwood, Andrew Poklepovic, & Paul Dent. (2018). Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells. Advances in cancer research. 137. 1–15. 8 indexed citations

10.

Booth, Laurence, Jane L. Roberts, Heath Ecroyd, et al.. (2016). AR‐12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication. Journal of Cellular Physiology. 231(10). 2286–2302. 33 indexed citations

11.

Tavallai, Mehrad, Laurence Booth, Jane L. Roberts, Andrew Poklepovic, & Paul Dent. (2016). Rationally Repurposing Ruxolitinib (Jakafi®) as a Solid Tumor Therapeutic. Frontiers in Oncology. 6. 142–142. 41 indexed citations

12.

Booth, Laurence, Jane L. Roberts, Heath Ecroyd, et al.. (2016). AR-12 Inhibits Chaperone Proteins Preventing Virus Replication and the Accumulation of Toxic Misfolded Proteins. Journal of Clinical & Cellular Immunology. 7(5). 6 indexed citations

13.

Cruickshanks, Nichola, Jane L. Roberts, Mehrad Tavallai, et al.. (2015). Differential regulation of autophagy and cell viability by ceramide species. Cancer Biology & Therapy. 16(5). 733–742. 21 indexed citations

14.

Booth, Laurence, Jane L. Roberts, & Paul Dent. (2015). HSPA5/Dna K May Be a Useful Target for Human Disease Therapies. DNA and Cell Biology. 34(3). 153–158. 14 indexed citations

15.

Roberts, Jane L., Mehrad Tavallai, Aida Nourbakhsh, et al.. (2015). GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases. Journal of Cellular Physiology. 230(10). 2552–2578. 42 indexed citations

16.

Booth, Laurence, Nichola Cruickshanks, Seyedmehrad Tavallai, et al.. (2014). Regulation of dimethyl-fumarate toxicity by proteasome inhibitors. Cancer Biology & Therapy. 15(12). 1646–1657. 25 indexed citations

17.

Roberts, Jane L., Laurence Booth, Adam Conley, et al.. (2014). PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. Cancer Biology & Therapy. 15(6). 758–767. 44 indexed citations

18.

Booth, Laurence, Jane L. Roberts, Adam Conley, et al.. (2013). HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells. Cancer Biology & Therapy. 15(3). 305–316. 33 indexed citations

19.

Gerry, Andrew B., W. Putt, Jane L. Roberts, et al.. (2006). Common variants of apolipoprotein A-IV differ in their ability to inhibit low density lipoprotein oxidation. Atherosclerosis. 192(2). 266–274. 42 indexed citations

20.

Roberts, Jane L., Paul A.B. Moretti, Andrew L. Darrow, et al.. (2004). An assay for sphingosine kinase activity using biotinylated sphingosine and streptavidin-coated membranes. Analytical Biochemistry. 331(1). 122–129. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact